Erythrodermic Psoriasis Treated with Apremilast.
| Autor: | Arcilla J; Department of Medicine, Loma Linda University School of Medicine., Joe D; Department of Medicine, Loma Linda University School of Medicine., Kim J; Department of Medicine, Loma Linda University School of Medicine., Kim Y; Department of Medicine, Loma Linda University School of Medicine., Truong VN; Department of Medicine, Loma Linda University School of Medicine., Jaipaul N; Department of Medicine, Loma Linda University School of Medicine; Department of Medicine, VA Loma Linda Healthcare System, Loma Linda, CA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Dermatology reports [Dermatol Reports] 2016 Sep 19; Vol. 8 (1), pp. 6599. Date of Electronic Publication: 2016 Sep 19 (Print Publication: 2016). |
| DOI: | 10.4081/dr.2016.6599 |
| Abstrakt: | Erythroderma is a rare potentially deadly exfoliative dermatitis characterized by diffuse cutaneous erythema which may be associated with multi-organ dysfunction. Therefore, it is imperative to recognize and treat it promptly. Erythrodermic psoriasis is the most common form of erythroderma. Management of this condition is largely based on aggressive supportive care and the use of anti-inflammatory immunosuppressive and biologic agents. We describe a case of psoriatic erythroderma which was triggered by withdrawal from systemic steroids and successfully treated with apremilast and cyclosporine. Apremilast induced atrial fibrillation limited its continued use after the initial response period. Competing Interests: the authors declare no potential conflict of interest. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|